Home
Reels
Grupos
Páginas
Más
Grupos Páginas Eventos Blogs Financiamiento
Iniciar sesión Registrarse
Night Mode
Autologous vs. Allogeneic: The CAR T Manufacturing Race
The promise of CAR T therapy is constrained by a manufacturing challenge: creating personalized treatments at scale is complex, time-consuming, and expensive. Autologous therapy—using the patient's own cells—requires a bespoke manufacturing process for each patient, with vein-to-vein times that can delay treatment. Allogeneic therapy—using donor cells—offers the...
0 Commentarios ·0 Acciones ·21 Views ·0 Vista previa
Please log in to like, share and comment!